Effector Therapeutics Inc (EFTR) Financials
Newest figures come from the 10-Q for Q1 FY2024, filed May 9, 2024. Each column of the statement tables below links to the filing it was taken from.
Effector Therapeutics Inc (EFTR) reported $0 in revenue for fiscal year 2023, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending is the core mechanic: modest sales have not funded recurring research, leaving cash losses to erode the equity base.
In FY2022, operating cash flow of-$25.9M nearly tracked net loss of-$22.7M , so reported losses translated into cash depletion rather than being dominated by non-cash charges. Debt-to-equity rose from 1.2x in FY2021 to 5.1x in FY2022, pairing ongoing cash consumption with a thinner equity base.
R&D intensity was unusually high: spending reached
The current ratio fell from 13.3x in FY2021 to 1.1x in FY2022, showing the short-term cushion narrowed sharply as operations consumed resources. Total liabilities of
Financial Health Signals
Effector Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Effector Therapeutics Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Effector Therapeutics Inc reported a net loss of $35.8M while operations used $29.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Effector Therapeutics Inc reported an operating loss of $33.8M against $2.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Effector Therapeutics Inc generated $0 in revenue in Q1 2024.
Effector Therapeutics Inc's EBITDA was -$8.4M in Q1 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.0% from the same quarter a year earlier.
Effector Therapeutics Inc reported -$8.8M in net income in Q1 2024. This represents an increase of 11.8% from the same quarter a year earlier.
Effector Therapeutics Inc earned -$2.16 per diluted share (EPS) in Q1 2024. Against the prior quarter it is up 86.4%.
Cash & Balance Sheet
Effector Therapeutics Inc recorded an outflow of $7.3M in free cash flow in Q1 2024, representing a cash shortfall after capex. This represents an increase of 4.9% from the same quarter a year earlier. Against the prior quarter it is down 29.5%.
Effector Therapeutics Inc held $15.5M in cash against $19.4M in long-term debt as of Q1 2024.
Not reported for Q1 2024.
Margins & Returns
Effector Therapeutics Inc's ROE was -1068.2% in Q1 2024, measuring profit generated per dollar of shareholder equity.
Not reported for Q1 2024.
Not reported for Q1 2024.
Not reported for Q1 2024.
Capital Allocation
Effector Therapeutics Inc invested $5.3M in research and development in Q1 2024. This represents a decrease of 19.7% from the same quarter a year earlier.
Effector Therapeutics Inc reported no capital expenditure in Q1 2024. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q1 2024.
EFTR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0-100.0% | $0-100.0% | $0 | N/A | $867K+103.0% | $2.0M+190.6% |
| R&D Expenses | $5.3M-19.7% | N/A | $5.4M-19.3% | $4.9M-29.5% | $6.6M+112.4% | N/A | $6.6M+32.1% | $6.9M+69.9% |
| SG&A Expenses | $3.1M+5.6% | N/A | $2.5M-28.3% | $3.0M0.0% | $2.9M-14.8% | N/A | $3.5M-15.4% | $3.0M+78.7% |
| Operating Income | -$8.4M+12.0% | N/A | -$7.9M+15.1% | -$7.9M+0.3% | -$9.5M-45.6% | N/A | -$9.3M-6.2% | -$7.9M-56.2% |
| EBITDA | -$8.4M+12.0% | N/A | -$7.8M+15.2% | -$7.8M+0.6% | -$9.5M-45.3% | N/A | -$9.2M-6.0% | -$7.9M-56.4% |
| Interest Expense | $749K+8.7% | N/A | $750K+31.6% | $722K+43.0% | $689K+44.1% | N/A | $570K+16.8% | $505K+5.2% |
| Net Income | -$8.8M+11.8% | N/A | -$8.3M+13.1% | -$8.4M-21.0% | -$10.0M-426.3% | N/A | -$9.6M-207.7% | -$6.9M-24.6% |
| EPS (Basic) | -$2.16+63.8% | -$15.84-7100.0% | -$0.13+43.5% | -$0.170.0% | -$5.96-7550.0% | -$0.22-114.3% | -$0.23-143.4% | -$0.17+95.6% |
| EPS (Diluted) | -$2.16 | -$15.84 | -$0.13 | -$0.170.0% | -$5.96 | -$0.22-123.7% | -$0.23 | -$0.17 |
| Diluted Shares (Avg) | 4M | N/A | 62M | 48M+16.3% | 2M | N/A | 41M | 41M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
EFTR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $27.1M+23.7% | $20.5M-29.3% | $20.2M-45.0% | $26.9M-38.1% | $21.9M-55.7% | $29.1M-46.2% | $36.7M-38.8% | $43.5M+204.4% |
| Current Assets | $26.3M+25.6% | $19.8M-29.2% | $19.3M-45.7% | $26.0M-38.6% | $20.9M-56.8% | $28.0M-47.0% | $35.5M-39.7% | $42.3M+251.4% |
| Cash & Equivalents | $15.5M+50.4% | $14.9M+70.8% | $5.4M-54.8% | $14.7M-10.0% | $10.3M-41.6% | $8.7M-82.5% | $11.9M-78.3% | $16.4M+50.3% |
| Short-Term Investments | $9.9M+13.5% | $3.5M-80.1% | $12.4M-41.1% | $10.3M-58.3% | $8.7M-69.0% | $17.6M | $21.1M | $24.7M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $26.3M-1.6% | $26.3M+4.6% | $24.1M-3.8% | $24.3M+2.0% | $26.7M+10.2% | $25.2M-31.5% | $25.1M-62.9% | $23.8M-84.9% |
| Current Liabilities | $25.6M-4.1% | $25.8M+2.9% | $23.6M-5.5% | $23.8M+0.7% | $26.7M+913.4% | $25.1M+530.3% | $25.0M-46.1% | $23.6M+336.8% |
| Non-Current Liabilities | $735K+725.8% | $543K+412.3% | $539K+338.2% | $555K+111.0% | $89K-99.6% | $106K-99.7% | $123K-99.4% | $263K-99.8% |
| Long-Term Debt | $19.4M-2.8% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M+7.7% |
| Total Equity | $827K+117.2% | -$5.8M-248.7% | -$4.0M-134.3% | $2.6M-86.9% | -$4.8M-119.1% | $3.9M-77.5% | $11.6M+250.7% | $19.6M+113.6% |
| Retained Earnings | -$188.2M-22.5% | -$179.4M-24.9% | -$170.2M-26.8% | -$161.9M-29.8% | -$153.6M-30.3% | -$143.6M-18.7% | -$134.3M+4.0% | -$124.7M+16.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
EFTR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.3M+4.7% | -$5.6M+17.9% | -$7.8M+5.2% | -$8.6M-93.6% | -$7.6M-17.5% | -$6.8M-35.4% | -$8.2M+9.7% | -$4.4M+23.7% |
| Depreciation & Amortization | $28K0.0% | $30K+11.1% | $26K+44.4% | $27K+800.0% | $28K+460.0% | $27K+440.0% | $18K+200.0% | $3K-53.1% |
| Stock-Based Compensation | $1.0M-13.5% | N/A | $1.1M-31.3% | $1.2M0.0% | $1.2M+2.5% | N/A | $1.6M+700.0% | $1.2M+500.0% |
| Capital Expenditures | $0-100.0% | $54K+315.4% | N/A | N/A | $13K | $13K | N/A | N/A |
| Free Cash Flow | -$7.3M+4.9% | -$5.6M+17.3% | N/A | N/A | -$7.7M | -$6.8M | N/A | N/A |
| Investing Cash Flow | -$6.3M-170.0% | $8.9M+147.0% | -$1.9M-152.9% | -$1.6M-149.7% | $9.0M+131.9% | $3.6M+10161.1% | $3.6M+60483.3% | $3.2M |
| Financing Cash Flow | $14.2M+6613.2% | $6.1M+16610.8% | $342K+208.1% | $14.6M+34790.5% | $212K-92.2% | -$37K-68.2% | $111K-99.8% | -$42K+46.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EFTR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1067.0% | -391.9% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1102.5% | -343.9% |
| Return on Equity | -1068.2% | N/A | N/A | -324.8%-289.6pp | N/A | N/A | -82.7% | -35.2% |
| Return on Assets | -32.6%+13.1pp | N/A | -41.2%-15.1pp | -31.1%-15.2pp | -45.7%-51.9pp | N/A | -26.1%-40.9pp | -15.9%+22.9pp |
| Current Ratio | 1.03+0.2x | 0.77-0.3x | 0.82-0.6x | 1.09-0.7x | 0.78-17.6x | 1.12-12.2x | 1.42+0.2x | 1.79-0.4x |
| Debt-to-Equity | 23.51 | N/A | N/A | 7.77+6.7x | N/A | 5.13+4.0x | 1.73 | 1.02 |
| Asset Turnover | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.020.0x | 0.050.0x |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.77), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Effector Therapeutics Inc EFTR | FY2023 | $0 | -$35.8M | N/A | N/A | — |
| Eloxx Pharmaceut ELOX | FY2025 | $0 | -$6.0M | N/A | $51.5M | — |
| Ampio Pharma AMPE | FY2023 | N/A | -$8.6M | N/A | $3K | — |
| Oncotelic Therapeutics Inc OTLC | FY2025 | N/A | $249.3M | N/A | $16.0M | — |
Where Effector Therapeutics Inc Ranks
Frequently Asked Questions
What is Effector Therapeutics Inc's annual revenue?
Effector Therapeutics Inc (EFTR) reported $0 in total revenue for fiscal year 2023. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Effector Therapeutics Inc's revenue growing?
Effector Therapeutics Inc (EFTR) revenue declined by 100.0% year-over-year, from $3.6M to $0 in fiscal year 2023.
Is Effector Therapeutics Inc profitable?
No, Effector Therapeutics Inc (EFTR) reported a net income of -$35.8M in fiscal year 2023.
What is Effector Therapeutics Inc's EBITDA?
Effector Therapeutics Inc (EFTR) had EBITDA of -$33.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Effector Therapeutics Inc have?
As of fiscal year 2023, Effector Therapeutics Inc (EFTR) had $14.9M in cash and equivalents against $20.0M in long-term debt.
What is Effector Therapeutics Inc's free cash flow?
Effector Therapeutics Inc (EFTR) recorded an outflow of $29.6M in free cash flow during fiscal year 2023. This represents a -13.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Effector Therapeutics Inc's operating cash flow?
Effector Therapeutics Inc (EFTR) recorded an outflow of $29.6M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are Effector Therapeutics Inc's total assets?
Effector Therapeutics Inc (EFTR) had $20.5M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Effector Therapeutics Inc's capital expenditures?
Effector Therapeutics Inc (EFTR) invested $97K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Effector Therapeutics Inc spend on research and development?
Effector Therapeutics Inc (EFTR) invested $22.9M in research and development during fiscal year 2023.
What is Effector Therapeutics Inc's current ratio?
Effector Therapeutics Inc (EFTR) had a current ratio of 0.77 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Effector Therapeutics Inc's return on assets (ROA)?
Effector Therapeutics Inc (EFTR) had a return on assets of -174.3% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
How does Effector Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, Effector Therapeutics Inc (EFTR) held $18.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.6M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Effector Therapeutics Inc's debt-to-equity ratio negative or not reported?
Effector Therapeutics Inc (EFTR) has negative shareholder equity of -$5.8M as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Effector Therapeutics Inc's Piotroski F-Score?
Effector Therapeutics Inc (EFTR) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Effector Therapeutics Inc's earnings high quality?
Effector Therapeutics Inc (EFTR) reported a net loss of $35.8M while operations used $29.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Effector Therapeutics Inc cover its interest payments?
Effector Therapeutics Inc (EFTR) reported an operating loss of $33.8M against $2.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.